Although the prognostic impact of BCL2 and BCL6 translocations has been disputed [13], [15], [22], [39], there is consensus that MYC translocation is a worse prognostic marker in patients with DLBCL treated CHOP, both in combination with and without rituximab [4], [17], [40]. The gene discussed is BCL2; the disease is diffuse large B-cell lymphoma.